New combo aims to shrink kidney tumors in Second-Line treatment
NCT ID NCT07469683
First seen Mar 16, 2026 · Last updated Apr 28, 2026 · Updated 9 times
Summary
This study tests whether adding the experimental drug SLC-3010 to the standard drug axitinib works better than axitinib alone for people with advanced clear cell kidney cancer that has already been treated once. About 78 participants will be randomly assigned to one of the two treatment groups. The main goal is to see if the combination shrinks tumors more effectively, while also monitoring side effects and survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Severance Hospital
RECRUITINGSeoul, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.